Eli Lilly & Co.’s stock rose 1.6% Wednesday, after the drug company announced plans to expand its U.S. manufacturing sites by adding four more locations this year, along with 13,000 high-wage jobs.

Eli Lilly (NYSE: LLY) stock has had plenty of good trading sessions over the past year or so, but Monday's sure wasn't among them. The storied pharmaceutical company's shares lost nearly 5% of ...

Presiding over the upward trajectory of Eli Lilly over the last eight years has been paying off nicely for CEO David Ricks. In 2024, his compensation package grew to $29.2 million, according to ...

RiverPark Advisors, an investment advisory firm and sponsor of the RiverPark family of mutual funds, released its “RiverPark Large Growth Fund” fourth quarter 2024 investor letter. A copy of ...

Earlier this week, Eli Lilly partnered up with telehealth providers LifeMD and Teladoc Health to offer its lower cost, single-vial Zepbound (tirzepatide) to patients in the virtual care companies ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro. In a sealed decision ...

Morgan Stanley noted that two compounding groups – the Outsourcing Facilities Association and North American Custom Laboratories – filed a motion for a preliminary injunction in a bid to stop ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Eli Lilly has reduced the prices of certain ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23 percent for ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 25 trades. If we consider the specifics of ...